echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Emgality (galcanezumab) for the treatment of paroxysmal cluster headache: Approved in Canada

    Emgality (galcanezumab) for the treatment of paroxysmal cluster headache: Approved in Canada

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cluster headache belongs to idiopathic headache disease—trigeminal autonomic cephalalgias (TACs).


    Paroxysmal cluster headache is a primary headache disease characterized by a sudden onset of severe pain on one side of the head.


    Eli Lilly and Company today announced that, Emgality® (galcanezumab) may reduce the frequency of seizures in adult patients with episodic cluster headache in the entire cluster period , and these patients for routine prevention of poor therapy response or intolerance, or contraindicated.


    Emgality® (galcanezumab) can reduce the frequency of paroxysmal cluster headache in adult patients during the entire cluster period Emgality® (galcanezumab) can reduce the frequency of episodes in adult patients with paroxysmal cluster headache during the entire cluster period.


    Dr.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.